Robert Sussman, MD
Pulmonary Disease · Summit, NJNPI 1831190990
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $491,984 of the $551,292 with a category attached, or 89.2%. GSK accounts for 70.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $128,298 and has fallen 59.8% since, to $51,622 in 2025. Among pulmonary disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 703 payments — averaging $784.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$386K
- Boehringer Ingelheim$70K
- Genentech USA, Inc.$37K
- AstraZeneca$26K
- Sanofi$16K
- Regeneron Healthcare Solutions, Inc.$12K
- plus $3K from 7 others
Across 15 payments — averaging $6231.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$30K
- GSK$26K
- Roche Products Limited$26K
- Insmed, Inc.$8K
- Novartis$4K
What the payments were for
- Consulting fees$28,7815%
- Speaking & faculty fees$491,98489%
- Travel & lodging$17,8523%
- Food & beverage$12,6662%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 469 | $386,402 |
| Boehringer Ingelheim | 73 | $69,901 |
| Genentech USA, Inc. | 43 | $36,724 |
| AstraZeneca | 45 | $26,393 |
| Sanofi | 20 | $16,363 |
| Regeneron Healthcare Solutions, Inc. | 31 | $12,297 |
| Amgen | 4 | $2,955 |
| Jazz Pharmaceuticals Inc. | 6 | $84 |
| Insmed, Inc. | 4 | $60 |
| Mylan Specialty L.p. | 4 | $60 |
| Alk-abello, Inc | 2 | $26 |
| Shire North American Group Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$194,294
- TRELEGY ELLIPTA$127,518
- OFEV$45,924
- DUPIXENT$23,860
- Esbriet$15,155
- TEZSPIRE$14,600
- SHINGRIX$13,045
- XOLAIR$4,174
- FASENRA$2,696
- ANORO ELLIPTA$2,250
How this compares
$551,292 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $153,835 |
| Breo ElliptaFluticasone/Vilanterol | 123 | $78,568 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 90 | $50,838 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $16,563 |
| Arnuity ElliptaFluticasone Furoate | 30 | $9,094 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,295 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $4,982 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $3,995 |
| Montelukast Sodium | 17 | $268 |
| Prednisone | 24 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $386,402 | $297,629391 claims |
| Boehringer IngelheimStiolto Respimat | $69,901 | $16,56318 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $4,98212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Summit
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
- Jeffrey MiskoffManasquan$176K
- Peter SacconeLinwood$149K
- Mazhar ElamirJersey City$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.